Mundipharma survey explores healthcare professional views on funding for new medicines
05 October 2015
70% of the healthcare professionals surveyed on the Mundipharma stand at the 9th Congress of the Europe Pain Federation (EFIC) said that they often face budget restrictions that prevent them from prescribing their preferred pain medication. 50% feel that they do not know enough about how medicines are funded within their healthcare system.
When asked what the most important factors to be considered are by healthcare systems to prioritise pain therapies funding, the health care professionals responded:
• Clinical benefit vs the current standard of care
• Quality of life measurements
• Real world evidence
The Mundipharma survey was answered by 109 healthcare professionals over the three day congress. The survey asked questions to healthcare professionals about the treatment and management of pain.
Developing innovative new pain medicines that health systems can say ‘yes’ to remains a challenge; it is critical that data is available not only to demonstrate efficacy and safety, but also cost effectiveness. At EFIC Mundipharma held a workshop entitled ‘Designing clinical trials with patient access in mind’ that brought together experts in funding decision making and health care professionals for discussion on what payers look for when assessing a new pain medical intervention.
Will Dunlop, Head of Market Access at Mundipharma said:
“Our workshop at EFIC is one example of how Mundipharma is collaborating with all stakeholders in the field of pain to look at how to put a value to non-traditional measures to support positive health economic evaluations and, ultimately, help patients gain access to innovative medicines”.